2-Methoxyestradiol analogue ENMD-1198 reduces breast cancer-induced osteolysis and tumor burden both in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 10, Issue 5, 2011, Pages 874-882

  Snoeks, Thomas J A ^a   Mol, Isabel M ^a   Que, Ivo ^a   Kaijzel, Eric L ^a   Löwik, Clemens W G M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ENMD 1198; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ESTRENES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OSTEOCLASTS; OSTEOLYSIS; PREGNANCY; TUMOR BURDEN;

EID: 79955989699     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0997     Document Type: Article

References (41)

1. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005;12:549-83. (Pubitemid 41482993)
2. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54. (Pubitemid 29122073)
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93. (Pubitemid 37328925)
4. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83. (Pubitemid 46718402)
5. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008;130:1091-103.
6. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a cross-sectional and longitudinal evaluation. Br J Cancer 2006;95:506-14. (Pubitemid 44232560)
7. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
8. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 41994;269:6271-4.
9. Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008;10:e7.
10. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s-6s.
11. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003;415 Suppl:S32-8.
12. Virk MS, Lieberman JR. Tumor metastasis to bone. Arthritis Res Ther 2007;9Suppl 1:S5.
13. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43. (Pubitemid 35424084)
14. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5. (Pubitemid 34525751)
15. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
16. + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010;70:4850-8.
17. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 2003;6:355-61. (Pubitemid 38173586)
18. Mooberry SL. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 2003;15:425-30. (Pubitemid 38147037)
19. Agoston GE, Shah JH, Suwandi L, Hanson AD, Zhan X, LaVallee TM, et al. Synthesis, antiproliferative, and pharmacokinetic properties of 3-and 17-double-modified analogs of 2-methoxyestradiol. Bioorg Med Chem Lett 2009;19:6241-4.
20. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 2008;7:1472-82.
21. Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, et al. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 2008;8:206.
22. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther 2010;9:1408-18.
23. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, et al. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs 2011;2:340-6.
24. Buijs JT, Que I, Lowik CW, Papapoulos SE, Van Der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009;44:380-6.
25. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032-45.
26. Van Der Pluijm G, Vloedgraven H, van Beek ER, Van Der Wee-Pals L, Lowik CW, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705. (Pubitemid 26349174)
27. Van Der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CW, Wetterwald A, et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005; 65:7682-90. (Pubitemid 41297242)
28. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-7. (Pubitemid 38496803)
29. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34. (Pubitemid 32995393)
30. Wetterwald A, Van Der Pluijm G, Que I, Sijmons B, Buijs J, Karperien M, et al. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol 2002;160:1143-53. (Pubitemid 34224600)
31. Deckers M, Van Der Pluijm G, Dooijewaard S, Kroon M, van Hinsbergh V, Papapoulos S, et al. Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants. Lab Invest 2001;81:5-15. (Pubitemid 32108635)
32. van Wijngaarden J, Snoeks TJ, van Beek ER, Bloys H, Kaijzel EL, van Hinsbergh V, et al. An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. Biochem Biophys Res Commun 2010;391:1161-5.
33. van Beek ER, Lowik CW, Van Der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999;14:722-9. (Pubitemid 29210598)
34. Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther 2007;6:2280-9. (Pubitemid 47294756)
35. Basu A, Haldar S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003;538:41-7. (Pubitemid 36287422)
36. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW , Niewolna M , et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009;4:e6896.
37. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75. (Pubitemid 38340305)
38. Maran A, Gorny G, Oursler MJ, Zhang M, Shogren KL, Yaszemski MJ, et al. 2-methoxyestradiol inhibits differentiation and is cytotoxic to osteoclasts. J Cell Biochem 12006;99:425-34.
39. Benedikt MB, Mahlum EW, Shogren KL, Subramaniam M, Spelsberg TC, Yaszemski MJ, et al. 2-Methoxyestradiol-mediated anti-tumor effect increases osteoprotegerin expression in osteosarcoma cells. J Cell Biochem 2010;109:950-6.
40. Cicek M, Iwaniec UT, Goblirsch MJ, Vrabel A, Ruan M, Clohisy DR, et al. 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res 2007;67:10106-11. (Pubitemid 350070780)
41. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.